SXTPW (60 Degrees Pharmaceuticals, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by SXTPW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | GEOFFREY S DOW | President and CEO | Buy | — | — |
| 2025-12-16 | GEOFFREY S DOW | President and CEO | Buy | — | — |
| 2025-12-12 | GEOFFREY S DOW | President and CEO | Buy | — | — |
| 2025-09-15 | GEOFFREY S DOW | President and CEO | A | — | — |
| 2025-08-14 | Kristen Landon | Chief Operating Officer | A | — | — |
| 2025-08-14 | Kristen Landon | Chief Operating Officer | A | — | — |
| 2025-06-09 | GEOFFREY S DOW | President and CEO | A | — | — |
| 2025-06-05 | CHERYL XU | Director | Buy | — | — |
| 2025-01-24 | GEOFFREY S DOW | President and CEO | A | — | — |
| 2025-01-24 | TYRONE MILLER | CFO | A | — | — |
| 2025-01-21 | GEOFFREY S DOW | President and CEO | A | — | — |
| 2025-01-21 | TYRONE MILLER | CFO | A | — | — |
| 2024-12-18 | CHERYL XU | Director | Buy | — | — |
| 2024-12-09 | GEOFFREY S DOW | President and CEO | Buy | — | — |
| 2024-11-21 | GEOFFREY S DOW | President and CEO | Buy | — | — |
| 2024-09-11 | CHERYL XU | Director | Buy | — | — |
| 2024-05-21 | STEPHEN TOOVEY | Director | A | — | — |
| 2024-05-21 | GEOFFREY S DOW | President and CEO | M | — | — |
| 2024-05-21 | Charles W Allen | Director | M | — | — |
| 2024-05-21 | PAUL FIELD | Director | M | — | — |
| 2024-05-21 | CHERYL XU | Director | M | — | — |
| 2024-05-21 | TYRONE MILLER | CFO | A | — | — |
| 2024-04-03 | THERAPEUTICS INTERNATIONAL SA KNIGHT | — | C | — | — |
| 2024-02-02 | GEOFFREY S DOW | President and CEO | Buy | — | — |
| 2024-02-02 | CHERYL XU | Director | MIXED | — | — |
| 2023-07-12 | TYRONE MILLER | Chief Financial Officer | A | — | — |
| 2023-07-12 | GEOFFREY S DOW | President and CEO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 78,803 | — |
| — | President and CEO | 35,250 | — |
| — | CFO | 26,370 | — |
| — | Director | 15,816 | — |
| — | Director | 14,000 | — |
| — | Director | 14,000 | — |
| — | Director | 14,000 | — |
| — | Chief Operating Officer | 4,540 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SXTPW quote page; the site-wide leaderboard is on the insider transactions hub.